{"product_id":"reta-32mg-pen-body-pharm","title":"Reta 32mg Pen - Body Pharm","description":"\u003cp data-start=\"379\" data-end=\"617\"\u003eReta trutide is a peptide currently under advanced clinical investigation for its activity across multiple metabolic pathways. It is designed to act on \u003cstrong data-start=\"549\" data-end=\"614\"\u003ethree key receptors involved in glucose and energy regulation\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-start=\"618\" data-end=\"731\"\u003e\n\u003cli data-start=\"618\" data-end=\"653\"\u003e\n\u003cp data-start=\"620\" data-end=\"653\"\u003eGLP-1 (glucagon-like peptide-1)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"654\" data-end=\"708\"\u003e\n\u003cp data-start=\"656\" data-end=\"708\"\u003eGIP (glucose-dependent insulinotropic polypeptide)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"709\" data-end=\"731\"\u003e\n\u003cp data-start=\"711\" data-end=\"731\"\u003eGlucagon receptors\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"733\" data-end=\"927\"\u003eThrough this \u003cstrong data-start=\"746\" data-end=\"774\"\u003etriple-agonist mechanism\u003c\/strong\u003e, retatrutide has been studied for its effects on insulin secretion, regulation of glucose production, gastric emptying, and appetite-related signalling.\u003c\/p\u003e\n\u003chr data-start=\"929\" data-end=\"932\"\u003e\n\u003ch3 data-start=\"934\" data-end=\"959\"\u003eClinical Trial Status\u003c\/h3\u003e\n\u003cp data-start=\"960\" data-end=\"1077\"\u003eAs of \u003cstrong data-start=\"966\" data-end=\"974\"\u003e2025\u003c\/strong\u003e, reta trutide remains \u003cstrong data-start=\"996\" data-end=\"1052\"\u003eunder investigation and is not yet formally approved\u003c\/strong\u003e for general medical use.\u003c\/p\u003e\n\u003cul data-start=\"1079\" data-end=\"1534\"\u003e\n\u003cli data-start=\"1079\" data-end=\"1280\"\u003e\n\u003cp data-start=\"1081\" data-end=\"1280\"\u003e\u003cstrong data-start=\"1081\" data-end=\"1109\"\u003ePhase 2 clinical studies\u003c\/strong\u003e reported significant outcomes, with participants experiencing an \u003cstrong data-start=\"1175\" data-end=\"1245\"\u003eaverage body-weight reduction of approximately 24.2% over 48 weeks\u003c\/strong\u003e under controlled trial conditions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1281\" data-end=\"1534\"\u003e\n\u003cp data-start=\"1283\" data-end=\"1534\"\u003e\u003cstrong data-start=\"1283\" data-end=\"1310\"\u003ePhase 3 clinical trials\u003c\/strong\u003e are ongoing and have reported \u003cstrong data-start=\"1341\" data-end=\"1422\"\u003econtinued, clinically meaningful effects consistent with earlier trial phases\u003c\/strong\u003e, further evaluating long-term safety, efficacy, and tolerability. Final data and regulatory review are pending.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"1536\" data-end=\"1617\"\u003eNo guarantees of outcome can be inferred outside of controlled clinical settings.\u003c\/p\u003e\n\u003chr data-start=\"1619\" data-end=\"1622\"\u003e\n\u003ch3 data-start=\"1624\" data-end=\"1652\"\u003eHow Retatrutide Compares\u003c\/h3\u003e\n\u003cp data-start=\"1653\" data-end=\"1725\"\u003eRetatrutide is often discussed alongside other incretin-based compounds:\u003c\/p\u003e\n\u003cul data-start=\"1727\" data-end=\"2050\"\u003e\n\u003cli data-start=\"1727\" data-end=\"1791\"\u003e\n\u003cp data-start=\"1729\" data-end=\"1791\"\u003e\u003cstrong data-start=\"1729\" data-end=\"1744\"\u003eSema glutide\u003c\/strong\u003e acts primarily as a \u003cstrong data-start=\"1765\" data-end=\"1791\"\u003eGLP-1 receptor agonist\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1792\" data-end=\"1875\"\u003e\n\u003cp data-start=\"1794\" data-end=\"1875\"\u003e\u003cstrong data-start=\"1794\" data-end=\"1809\"\u003eTirze patide\u003c\/strong\u003e is a \u003cstrong data-start=\"1815\" data-end=\"1831\"\u003edual agonist\u003c\/strong\u003e, targeting both \u003cstrong data-start=\"1848\" data-end=\"1875\"\u003eGLP-1 and GIP receptors\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1876\" data-end=\"2050\"\u003e\n\u003cp data-start=\"1878\" data-end=\"2050\"\u003e\u003cstrong data-start=\"1878\" data-end=\"1893\"\u003eReta trutide\u003c\/strong\u003e is a \u003cstrong data-start=\"1899\" data-end=\"1917\"\u003etriple agonist\u003c\/strong\u003e, additionally engaging the \u003cstrong data-start=\"1945\" data-end=\"1966\"\u003eglucagon receptor\u003c\/strong\u003e, which differentiates its investigational profile from earlier-generation compounds\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003chr data-start=\"2052\" data-end=\"2055\"\u003e\n\u003ch3 data-start=\"2057\" data-end=\"2082\"\u003eImportant Information\u003c\/h3\u003e\n\u003cul data-start=\"2083\" data-end=\"2441\"\u003e\n\u003cli data-start=\"2083\" data-end=\"2145\"\u003e\n\u003cp data-start=\"2085\" data-end=\"2145\"\u003e\u003cmeta charset=\"utf-8\"\u003eSupplied as a \u003cstrong data-start=\"269\" data-end=\"298\"\u003epre-filled injectable pen\u003c\/strong\u003e\u003cbr\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2212\" data-end=\"2265\"\u003e\n\u003cp data-start=\"2214\" data-end=\"2265\"\u003eRetatrutide remains an \u003cstrong data-start=\"2237\" data-end=\"2265\"\u003einvestigational compound\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2266\" data-end=\"2367\"\u003e\n\u003cp data-start=\"2268\" data-end=\"2367\"\u003eConsultation with a \u003cstrong data-start=\"2288\" data-end=\"2320\"\u003elicensed healthcare provider\u003c\/strong\u003e is essential prior to any consideration of use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2368\" data-end=\"2441\"\u003e\n\u003cp data-start=\"2370\" data-end=\"2441\"\u003eResults observed in clinical trials may not reflect real-world outcomes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"2443\" data-end=\"2446\"\u003e\n\u003ch3 data-start=\"2448\" data-end=\"2481\"\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003cp data-start=\"2482\" data-end=\"2588\"\u003eThis product is supplied strictly on an \u003cstrong data-start=\"2522\" data-end=\"2550\"\u003einformed purchaser basis\u003c\/strong\u003e. By purchasing, you acknowledge that:\u003c\/p\u003e\n\u003cul data-start=\"2590\" data-end=\"3029\"\u003e\n\u003cli data-start=\"2590\" data-end=\"2671\"\u003e\n\u003cp data-start=\"2592\" data-end=\"2671\"\u003eYou have independently researched this product and its investigational status\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2672\" data-end=\"2748\"\u003e\n\u003cp data-start=\"2674\" data-end=\"2748\"\u003eYou have consulted, or will consult, a qualified healthcare professional\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2749\" data-end=\"2859\"\u003e\n\u003cp data-start=\"2751\" data-end=\"2859\"\u003eYou understand that retatrutide is \u003cstrong data-start=\"2786\" data-end=\"2806\"\u003enot yet approved\u003c\/strong\u003e and remains subject to ongoing clinical evaluation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2860\" data-end=\"2943\"\u003e\n\u003cp data-start=\"2862\" data-end=\"2943\"\u003eThe seller provides \u003cstrong data-start=\"2882\" data-end=\"2941\"\u003eno medical advice, treatment claims, or dosing guidance\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2944\" data-end=\"3029\"\u003e\n\u003cp data-start=\"2946\" data-end=\"3029\"\u003eThe \u003cstrong data-start=\"2950\" data-end=\"3029\"\u003eonus of lawful, safe, and appropriate use rests entirely with the purchaser\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"LIFE.OS","offers":[{"title":"Default Title","offer_id":53118538023230,"sku":"BPRETA32MGPEN","price":2500.0,"currency_code":"ZAR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0970\/9826\/8990\/files\/HD-RETA-32MG.png?v=1773167026","url":"https:\/\/life-os.co.za\/products\/reta-32mg-pen-body-pharm","provider":"LIFE.OS","version":"1.0","type":"link"}